Medicine Information

Imbac

Name: Imbac
Brand: Imbac
Rating: 4.5 (117 reviews)

Injection (for intravenous infusion)Imipenem 500 mg / Cilastatin 500 mgCarbapenem AntibioticATC: J01DH51

Generic Name

Imipenem and Cilastatin

Manufacturer

Example Pharmaceutical Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
imbac 500 mg injection	৳ 1,200.00	N/A

Description

Overview of the medicine

Imbac-500 mg injection is a broad-spectrum antibiotic used to treat a wide range of severe bacterial infections. It contains Imipenem, a carbapenem antibiotic, and Cilastatin, an enzyme inhibitor, which together provide potent bactericidal activity.

Uses & Indications

Lower respiratory tract infections (e.g., pneumonia)

Intra-abdominal infections (e.g., peritonitis)

Urinary tract infections (complicated and uncomplicated)

Gynecological infections

Skin and soft tissue infections

Bone and joint infections

Septicemia

Endocarditis

Bacterial meningitis

Dosage

Adults

Usually 500 mg Imipenem (with 500 mg Cilastatin) every 6-8 hours by intravenous infusion. Max daily dose is 4 g Imipenem (with 4 g Cilastatin). Dosage varies based on severity of infection and susceptibility of causative organisms.

Elderly

Dosage should be adjusted based on renal function, similar to adults with renal impairment.

Renal_impairment

Significant dose reduction and/or increased dosing interval required based on creatinine clearance. Consult specific dosing tables.

How to Take

Administer by intravenous infusion over 20 to 60 minutes. The reconstituted solution must be further diluted before infusion. Do not administer by intramuscular or bolus injection.

Mechanism of Action

Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell lysis and death. Cilastatin is a dehydropeptidase I inhibitor that prevents the metabolism of imipenem in the kidneys, ensuring higher and more prolonged concentrations of active imipenem.

Pharmacokinetics

Onset

Rapid onset of action following intravenous infusion.

Excretion

Primarily excreted unchanged in the urine (70% for imipenem and 70-75% for cilastatin within 10 hours).

Half life

Approximately 1 hour for both imipenem and cilastatin.

Absorption

Administered intravenously, resulting in 100% bioavailability.

Metabolism

Imipenem is extensively metabolized in the kidneys by dehydropeptidase I, which is inhibited by cilastatin. Cilastatin is not metabolized.

Side Effects

Contraindications

Known hypersensitivity to imipenem, cilastatin, or any other carbapenem antibiotics.
History of severe hypersensitivity reaction to other beta-lactam antibiotics (e.g., penicillins, cephalosporins).

Drug Interactions

Probenecid

Increases imipenem and cilastatin plasma levels and half-life, not recommended for co-administration.

Ganciclovir

Concomitant use may increase the risk of generalized seizures.

Valproic acid

May decrease valproic acid plasma concentrations, potentially leading to subtherapeutic levels and increased risk of seizures.

Storage

Store intact vials at controlled room temperature (20-25°C), protected from light. Do not freeze. Reconstituted solutions should be used immediately or stored as per specific manufacturer guidelines.

Overdose

In the event of an overdose, symptomatic and supportive treatment should be initiated. Hemodialysis may be useful for removing imipenem and cilastatin from the circulation.

Pregnancy & Lactation

Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Imipenem and cilastatin are excreted in human milk; use with caution in nursing mothers.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

Single vial packBox of 10 vials

Shelf Life

Typically 2 to 3 years when stored as per recommendations. Reconstituted solutions have limited stability.

Availability

Available in hospitals and retail pharmacies.

Approval Status

Approved by major regulatory bodies globally, including FDA/DGDA.

Patent Status

Generic versions available, original patent expired.

WHO Essential Medicine

Yes

Clinical Trials

Imipenem/Cilastatin has undergone extensive clinical trials demonstrating its efficacy and safety in various severe bacterial infections. Ongoing research explores its role in antibiotic resistance management and new therapeutic applications.

Lab Monitoring

Monitor renal function (creatinine, BUN)
Monitor liver function tests (AST, ALT, ALP)
Complete blood count (CBC) to check for hematologic abnormalities.

Doctor Notes

Emphasize judicious use of carbapenems to mitigate the development of antimicrobial resistance.
Careful dose adjustment is critical in patients with renal impairment to prevent accumulation and adverse effects.
Monitor patients for CNS side effects, especially those with pre-existing seizure disorders or compromised renal function.

Patient Guidelines

Complete the full course of treatment as prescribed, even if you feel better.
Report any severe or persistent side effects to your doctor immediately.
Do not share this medicine with others, even if they have similar symptoms.

Missed Dose Advice

If a dose is missed, administer it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and resume your regular dosing schedule. Do not double the dose.